文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[Mechanism and prevention strategies of neurotoxicity in CAR-T treatment of B cell tumors].

作者信息

Zhang Q, Xiao Y

机构信息

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):787-792. doi: 10.3760/cma.j.issn.0253-2727.2021.09.016.

DOI:10.3760/cma.j.issn.0253-2727.2021.09.016
PMID:34753239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8607045/
Abstract
摘要

相似文献

[1]
[Mechanism and prevention strategies of neurotoxicity in CAR-T treatment of B cell tumors].

Zhonghua Xue Ye Xue Za Zhi. 2021-9-14

[2]
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.

Curr Res Transl Med. 2018-4-3

[3]
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.

Expert Opin Biol Ther. 2019-7-25

[4]
Toxicities of CD19 CAR-T cell immunotherapy.

Am J Hematol. 2019-3-6

[5]
CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.

J Immunol Res. 2020

[6]
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.

Br J Haematol. 2018-11-8

[7]
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.

Clin Lymphoma Myeloma Leuk. 2021-4

[8]
Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).

J Cancer Res Clin Oncol. 2019-7

[9]
Post-infusion CAR T cells identify patients resistant to CD19-CAR therapy.

Nat Med. 2022-9

[10]
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.

Immunotherapy. 2021-3

本文引用的文献

[1]
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities.

Front Immunol. 2021

[2]
Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy Ameliorating Endothelial Activation.

Front Immunol. 2021

[3]
Return-to-work, disabilities and occupational health in the age of COVID-19.

Scand J Work Environ Health. 2021-7-1

[4]
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.

Nat Rev Immunol. 2022-2

[5]
Reactions Related to CAR-T Cell Therapy.

Front Immunol. 2021

[6]
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.

Onco Targets Ther. 2021-3-26

[7]
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction.

Front Immunol. 2021

[8]
Understanding and treating the inflammatory adverse events of cancer immunotherapy.

Cell. 2021-3-18

[9]
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL.

Bone Marrow Transplant. 2021-3

[10]
Neurological updates: neurological complications of CAR-T therapy.

J Neurol. 2021-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索